Developing a human pluripotent stem cell-based strategy for treating Hirschsprung disease
Developing a human pluripotent stem cell-based strategy for treating Hirschsprung disease
批准号:
MR/V002163/1
负责人:
Anestis Tsakiridis
金额:
$129.6万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
先天性巨结肠症是一种威胁生命的肠道疾病,由胃肠道最远端缺乏固有神经细胞(无神经节细胞症)引起。大约每5000名活产儿中就有一人患有该病,使其成为影响肠道的最常见的先天性疾病之一。鉴于肠道固有神经细胞(肠神经细胞)调节正常肠道功能所需的收缩,先天性巨结肠患者缺乏这些细胞会导致严重的便秘或肠梗阻。唯一可用的治疗方法是外科手术切除受影响的肠道部分,并进行“拉出”程序,这需要将健康的肠道部分连接到肛门。然而,手术需要保留包括肛门括约肌在内的部分异常肠道,这可能是大多数先天性巨结肠患者长期(通常是终生)胃肠道问题和生活质量低下的部分原因。管理这种情况所需的手术、再入院和门诊医院预约给医疗保健系统带来了巨大的负担。在了解肠道固有(或肠道)神经系统的发育和疾病发病机制方面的最新进展,以及再生医学的相当大进展,突出了替代治疗的潜力,如细胞替代疗法。在正常的胚胎发育过程中,肠道神经系统是由一群称为神经脊细胞的瞬时细胞群体衍生而来的,这些细胞从神经管迁移到胃肠道。在先天性巨结肠症中,这些细胞不能在远端肠道定植,留下一段可变的无神经节细胞增多症。动物模型实验表明,肠神经系统前体/干细胞(来源于原始神经脊细胞的衍生品,取自小鼠肠道或小鼠胚胎干细胞)移植到无神经节细胞的肠道内,具有向肠道神经元分化和定植的能力。从人类出生后肠道外植体中获得的类似神经前体细胞已被证明在先天性巨结肠患者的无神经节细胞肠道外植体中有效地定植和分化。然而,从肠道中获取这样的人类神经前体细胞是困难的,并且随着出生后年龄的增加而变得更加困难。因此,尽管这种临床前试验表明,细胞疗法应该是治疗先天性巨结肠的一个可行的选择,但从出生后肠道中获得人类肠道神经元仍然是基于细胞疗法发展的瓶颈。多能干细胞提供了一个有吸引力的替代来源,在数量和为任务量身定做细胞特性方面都有很大的潜力生成合适的细胞用于治疗。我们最近已经开发出有效的方案来从人的多能干细胞中产生人的神经脊细胞和肠道神经系统的祖细胞。在这个项目中,我们将测试这些祖细胞在移植后纠正动物和患者来源的先天性巨结肠模型中缺乏肠道神经元的能力。我们还将优化目前从多能干细胞中培养和纯化人类肠道神经系统前体细胞的方法,并将开发一种新的改进的先天性巨结肠动物模型。通过这种方式,我们将通过移植来自人类多能干细胞的细胞来重新支配受影响的肠道部分,为治疗先天性巨结肠的再生医学方法奠定临床前基础。首先,我们的目标将是通过对常规手术后剩余的短节进行神经支配来改善当前治疗的结果。
英文摘要
Hirschsprung disease is a life-threatening intestinal disorder caused by an absence of intrinsic nerve cells (aganglionosis) in the most distal gastrointestinal tract. It occurs in approximately 1 in 5000 live births, making it one of the most common congenital diseases affecting the gut. Given that intrinsic gut nerve cells (enteric neurons) mediate the contractions necessary for normal gut function, their absence in Hirschsprung patients causes severe constipation or intestinal obstruction. The only treatment available is surgical removal of the affected part of the bowel combined with a 'pull through' procedure, which entails connecting the healthy part of the gut to the anus. However, the surgery necessitates retention of part of the abnormal gut including the anal sphincter, which is likely to account in part for the long-term, often life-long, gastrointestinal problems and poor quality of life suffered by the majority of patients with Hirschsprung disease. Surgery, readmissions and outpatients hospital appointments required for management of this condition present a significant burden for the healthcare system. Recent advances in the understanding of development of the gut's intrinsic (or enteric) nervous system and pathogenesis of the disease, as well as considerable progress in regenerative medicine, have highlighted potential for alternative treatments, such as cell replacement therapy.During normal embryonic development, the enteric nervous system is derived from a transient population of cells termed neural crest cells that migrate from the neural tube to innervate the gastrointestinal tract. In Hirschsprung disease these cells fail to colonize the distal gut leaving a variable segment of aganglionosis. Experiments in animal models have demonstrated that transplantation of enteric nervous system progenitor/stem cells (derivatives of the original neural crest cells and harvested from mouse gut explants or mouse embryonic stem cells) have the ability to differentiate into enteric neurons and colonize when transplanted into aganglionic gut explants. Similar neuronal progenitor cells obtained from human postnatal gut explants have been shown to effectively colonize and differentiate within aganglionic gut explants of Hirschsprung patients. However, the harvesting of such human nerve progenitor cells from gut is difficult and becomes more so with increasing post-natal age. Therefore, although such preclinical testing has demonstrated that cell therapy should be a viable option for curing Hirschsprung disease, the availability of human enteric neurons from post-natal gut remains a bottleneck for development of cell-based therapies.An attractive alternative source is offered by pluripotent stem cells, where there is significant potential of generating appropriate cells for therapy both in terms of numbers and tailoring cell properties for the task. We have recently developed efficient protocols to generate human neural crest cells and enteric nervous system progenitors from human pluripotent stem cells. In this project, we will test the ability of these progenitors to correct for the lack of enteric neurons in animal and patient-derived models of Hirschsprung disease following transplantation. We will also optimise the current methods of generating and purifying human enteric nervous system progenitors from pluripotent stem cellsand will develop a new improved animal model of Hirschsprung disease. In this way, we will establish the pre-clinical basis for a regenerative medicine approach for treating Hirschsprung disease by transplantation of cells derived from human pluripotent stem cells to re-innervate the affected part of the gut. In the first instance our goal will be to improve the outcome of current treatments by innervation of the short section remaining after routine surgery.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.7554/elife.74263
发表时间:
2022-09-26
期刊:
eLife
影响因子:
7.7
作者:
[Gogolou A, Souilhol C, Granata I, Wymeersch FJ, Manipur I, Wind M, Frith TJR, Guarini M, Bertero A, Bock C, Halbritter F, Takasato M, Guarracino MR, Tsakiridis A]
通讯作者:
Tsakiridis A
Early anteroposterior regionalisation of human neural crest is shaped by a pro-mesodermal factor
人类神经嵴的早期前后区域化是由前中胚层因子塑造的
DOI:
10.1101/2021.09.24.461516
发表时间:
2021
期刊:
影响因子:
--
作者:
[Gogolou A]
通讯作者:
Gogolou A
DOI:
10.1016/j.stemcr.2023.11.012
发表时间:
2024-01-09
期刊:
STEM CELL REPORTS
影响因子:
5.9
作者:
[Andrews, Peter W., Gokhale, Paul J.]
通讯作者:
Gokhale, Paul J.
Notch signalling influences cell fate decisions and HOX gene induction in axial progenitors
Notch信号传导影响轴向祖细胞的细胞命运决定和HOX基因诱导
DOI:
10.1101/2023.06.16.545269
发表时间:
2023
期刊:
影响因子:
--
作者:
[Cooper F]
通讯作者:
Cooper F
DOI:
10.1042/bst20211152
发表时间:
2022-02-28
期刊:
Biochemical Society transactions
影响因子:
3.9
作者:
[]
通讯作者:
Human enteric nervous system progenitor dynamics during development and disease
-
批准号:MR/Y013476/1
-
项目类别:Research Grant
-
资助金额:$137.68万
-
财政年份:2024
-
负责人:Anestis Tsakiridis
-
依托单位:
Screening for regulators of human embryonic axis elongation in vitro
-
批准号:BB/P000444/1
-
项目类别:Research Grant
-
资助金额:$53.19万
-
财政年份:2017
-
负责人:Anestis Tsakiridis
-
依托单位:
国内基金
海外基金
登录
查看更多内容
靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:胡文静
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
自闭症相关基因CHD8在非人灵长类大脑发育中的作用
-
批准号:32100783
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:赵晖
-
依托单位:
HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
-
批准号:81960115
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2019
-
负责人:江建宁
-
依托单位:
HPV导致子宫颈上皮-间充质细胞转化的研究
-
批准号:81101974
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:江静
-
依托单位:
普适计算环境下基于交互迁移与协作的智能人机交互研究
-
批准号:61003219
-
项目类别:青年科学基金项目
-
资助金额:7.0万元
-
批准年份:2010
-
负责人:沈耀
-
依托单位:
DARC在基底细胞样乳腺癌中作用机制的研究
-
批准号:81001172
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:王杰
-
依托单位:
基于自适应表面肌电模型的下肢康复机器人“Human-in-Loop”控制研究
-
批准号:61005070
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:李庆玲
-
依托单位:
子宫颈癌中HPV E6对hTERT基因调控的研究
-
批准号:81001157
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2010
-
负责人:赵超
-
依托单位:
人真皮多潜能成纤维细胞向胰岛素分泌细胞分化的体外及体内研究
-
批准号:30800231
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2008
-
负责人:陈付国
-
依托单位: